KEYNOTE-024 demonstrated that pembrolizumab was associated with significantly longer PFS and OS in advanced NSCLC patients with a PD-L1 (tumor) score ≥ 50% 19, 42, while the Checkmate-026 study reported that nivolumab failed to show any benefit compared with standard chemotherapy based on PD-L1 expression ≥ 5%. This evidence concerns the gene CD274 and non-small cell lung carcinoma.